Recent clinical studies have indicated that the combination therapy of IL2 with peptide vaccines had increased objective responses in cancer patients compared to IL2 alone, demonstrating that the monotherapy of IL2 can be enhanced by synthetic peptide cancer vaccines (12, 13). The gene discussed is IL2; the disease is cancer.